Abstracts tagged "Lung Disease"

Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Jean-Paul Makhzoum¹, Raashid Luqmani², Richard A. Watts³, Anthea Craven⁴, Peter A. Merkel⁵ and Christian Pagnoux⁶, ¹Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, The Ipswich Hospital, Ipswich, Great Britain, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford University Hospitals, Oxford, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁶Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 24 • 2017 ACR/ARHP Annual Meeting
Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis
Priti Prasad¹, Michael Fishbein², Rohan Sharma³, Ramesh Halder⁴, Isela Valera¹ and Ram R. Singh⁵, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ³Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los angeles, CA, ⁴Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ⁵Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Lung is involved in up to 50% patients with SLE. Among manifestations of pulmonary lupus, pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH) carry a…
Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…
Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 1994 • 2016 ACR/ARHP Annual Meeting
Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Bryant R. England^1,2, Harlan Sayles³, Kaleb Michaud^3,4, Liron Caplan⁵, Lisa A. Davis^6,7, Grant W. Cannon⁸, Brian Sauer⁹, E. Blair Solow¹⁰, Andreas Reimold¹¹, Gail S. Kerr¹², Pascale Schwab¹³, Joshua F. Baker¹⁴, Namrata Singh¹⁵ and Ted R. Mikuls¹⁶, ¹VA Nebraska-Western Iowa, Omaha, NE, ²Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS, ⁵Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁷Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁸Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹¹Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹²Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, ¹³Div Arth & Rheum Dis, Portland VA and Oregon Health & Science University, Portland, OR, ¹⁴Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁵Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ¹⁶Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While the impact of interstitial lung disease (ILD) on mortality in RA has been demonstrated, less is known about the influence of other lung…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 2188 • 2016 ACR/ARHP Annual Meeting
Association Between Extent of Symptomatic Joint Involvement in Osteoarthritis and Comorbid Lung Disease in Patients Scheduled for Joint-Replacement Surgery
Anthony V. Perruccio^1,2,3, Rajiv Gandhi⁴, J. Denise Power^5,6 and Elizabeth M. Badley⁷, ¹The Arthritis Program, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Arthritis Program, Toronto, ON, Canada, ⁵Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Dalla Lana School of Public Health, Toronto, ON, Canada, ⁷Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Comorbidity is highly prevalent in osteoarthritis (OA), although the origin of this is not well understood. The presence of multi-joint symptoms in OA, and…
Abstract Number: 2189 • 2016 ACR/ARHP Annual Meeting
The Association of Arthritis and Lung Diseases: A Population-Based Study
Elizabeth M. Badley^1,2, Marcia Maguire¹ and Anthony V. Perruccio^1,3, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: While rheumatoid arthritis is associated with a number of different lung conditions, the relationship with osteoarthritis, overwhelmingly the most frequent type of arthritis in…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].